These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9237705)

  • 1. Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients.
    Barditch-Crovo P; Toole J; Hendrix CW; Cundy KC; Ebeling D; Jaffe HS; Lietman PS
    J Infect Dis; 1997 Aug; 176(2):406-13. PubMed ID: 9237705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.
    Deeks SG; Collier A; Lalezari J; Pavia A; Rodrigue D; Drew WL; Toole J; Jaffe HS; Mulato AS; Lamy PD; Li W; Cherrington JM; Hellmann N; Kahn J
    J Infect Dis; 1997 Dec; 176(6):1517-23. PubMed ID: 9395363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.
    Kahn J; Lagakos S; Wulfsohn M; Cherng D; Miller M; Cherrington J; Hardy D; Beall G; Cooper R; Murphy R; Basgoz N; Ng E; Deeks S; Winslow D; Toole JJ; Coakley D
    JAMA; 1999 Dec 22-29; 282(24):2305-12. PubMed ID: 10612317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial.
    Fisher EJ; Chaloner K; Cohn DL; Grant LB; Alston B; Brosgart CL; Schmetter B; El-Sadr WM; Sampson J;
    AIDS; 2001 Sep; 15(13):1695-700. PubMed ID: 11546945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy.
    Mulato AS; Lamy PD; Miller MD; Li WX; Anton KE; Hellmann NS; Cherrington JM
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1620-8. PubMed ID: 9660994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial.
    ADHOC International Steering Committee
    HIV Med; 2002 Oct; 3(4):229-38. PubMed ID: 12444940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults.
    Deeks SG; Barditch-Crovo P; Lietman PS; Hwang F; Cundy KC; Rooney JF; Hellmann NS; Safrin S; Kahn JO
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2380-4. PubMed ID: 9736567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose pharmacokinetics and safety of the oral antiviral compound adefovir dipivoxil in children infected with human immunodeficiency virus type 1. The Pediatrics AIDS Clinical Trials Group.
    Hughes WT; Shenep JL; Rodman JH; Fridland A; Willoughby R; Blanchard S; Purdue L; Coakley DF; Cundy KC; Culnane M; Zimmer B; Burchett S; Read JS
    Antimicrob Agents Chemother; 2000 Apr; 44(4):1041-6. PubMed ID: 10722509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.
    Peters MG; Andersen J; Lynch P; Liu T; Alston-Smith B; Brosgart CL; Jacobson JM; Johnson VA; Pollard RB; Rooney JF; Sherman KE; Swindells S; Polsky B;
    Hepatology; 2006 Nov; 44(5):1110-6. PubMed ID: 17058225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
    Marcellin P; Chang TT; Lim SG; Tong MJ; Sievert W; Shiffman ML; Jeffers L; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
    N Engl J Med; 2003 Feb; 348(9):808-16. PubMed ID: 12606735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Wulfsohn MS; Xiong S; Fry J; Brosgart CL;
    N Engl J Med; 2003 Feb; 348(9):800-7. PubMed ID: 12606734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Brosgart CL; Borroto-Esoda K; Arterburn S; Chuck SL;
    Gastroenterology; 2006 Dec; 131(6):1743-51. PubMed ID: 17087951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults.
    Barditch-Crovo P; Deeks SG; Collier A; Safrin S; Coakley DF; Miller M; Kearney BP; Coleman RL; Lamy PD; Kahn JO; McGowan I; Lietman PS
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2733-9. PubMed ID: 11557462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
    Skowron G; Kuritzkes DR; Thompson MA; Squires KE; Goodwin SD; Dusak BA; Tolson JM; Stevens M; Yuen GJ; Rooney JF;
    J Infect Dis; 2002 Oct; 186(7):1028-33. PubMed ID: 12232846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adefovir dipivoxil. Bis-POM PMEA, GS 0840, GS 840, Piv2PMEA.
    Drugs R D; 1999 Nov; 2(5):303-5. PubMed ID: 10728465
    [No Abstract]   [Full Text] [Related]  

  • 16. Adefovir dipivoxil: a review of its use in chronic hepatitis B.
    Dando T; Plosker G
    Drugs; 2003; 63(20):2215-34. PubMed ID: 14498759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
    Hadziyannis SJ; Tassopoulos NC; Heathcote EJ; Chang TT; Kitis G; Rizzetto M; Marcellin P; Lim SG; Goodman Z; Ma J; Arterburn S; Xiong S; Currie G; Brosgart CL;
    N Engl J Med; 2005 Jun; 352(26):2673-81. PubMed ID: 15987916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
    Marcellin P; Heathcote EJ; Buti M; Gane E; de Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Washington MK; Sorbel J; Anderson J; Snow-Lampart A; Mondou E; Quinn J; Rousseau F
    N Engl J Med; 2008 Dec; 359(23):2442-55. PubMed ID: 19052126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adefovir dipivoxil.
    Noble S; Goa KL
    Drugs; 1999 Sep; 58(3):479-87; discussion 488-9. PubMed ID: 10493275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.
    Benhamou Y; Thibault V; Vig P; Calvez V; Marcelin AG; Fievet MH; Currie G; Chang CG; Biao L; Xiong S; Brosgart C; Poynard T
    J Hepatol; 2006 Jan; 44(1):62-7. PubMed ID: 16274835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.